Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton Sells 4,173 Shares

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 4,173 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $4.88, for a total transaction of $20,364.24. Following the completion of the sale, the chief executive officer now owns 740,019 shares of the company’s stock, valued at approximately $3,611,292.72. This represents a 0.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cryoport Price Performance

Shares of NASDAQ CYRX opened at $6.65 on Wednesday. The stock has a market capitalization of $328.72 million, a price-to-earnings ratio of -1.97 and a beta of 1.67. The business has a 50-day moving average of $7.19 and a 200-day moving average of $7.54. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. Cryoport, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $20.11.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The company had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter in the previous year, the business earned ($0.29) EPS. As a group, sell-side analysts predict that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cryoport

Several hedge funds have recently modified their holdings of CYRX. Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after acquiring an additional 2,120 shares in the last quarter. Lazard Asset Management LLC bought a new position in Cryoport during the fourth quarter worth about $51,000. Avanza Fonder AB acquired a new position in Cryoport during the fourth quarter worth approximately $64,000. Quarry LP acquired a new position in Cryoport during the fourth quarter worth approximately $69,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Cryoport during the third quarter worth approximately $82,000. Institutional investors own 92.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on CYRX shares. Guggenheim started coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Cryoport in a report on Wednesday, March 5th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $12.29.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.